CEO SUMMARY: THE DARK REPORT presents its newest biannual review of macro trends reshaping the anatomic pathology profession. These macro trends reveal a profession undergoing change and transformation on multiple fronts. New competitors are crowding into the market, payers and accrediting agencies are demanding higher standards of performance, and a host of new technologies are
Tag: cellular imaging
CEO SUMMARY: Following three years of rapid growth in specimen volume and revenues, US LABS has accepted a purchase offer from Laboratory Corporation of America. Both US LABS’ fast growth and its sale to a national lab demonstrate that there is still opportunity in laboratory testing—and that one of the two blood brothers is ever
CEO SUMMARY: It is no coincidence that another public company is shifting its business focus and expanding its efforts to capture cancer-related anatomic pathology specimens. Demographic trends predict a steady increase in the number of new cancer cases yearly, while new technologies are giving physicians more effective ways to detect cancer and treat it. That
CEO SUMMARY: Three new business strategies are moving ChromaVision into different segments of the laboratory testing marketplace. The company has built a new laboratory facility and will support local pathology groups with advanced diagnostic technology. It is also expanding its presence in the research and development area of pharmacodiagnostics, with an emphasis on oncology.
Business Week Magazine placed Bio-Reference Laboratories, Inc. (BRLI) on its 2004 list of the Top 100 Hot Growth Stocks. BRLI, based in Elmwood Park, New Jersey, was ranked 16th. Business Week announced the list in its June 7, 2004 issue. With steady growth in revenues and net profits in recent years, BRLI’s shares have performed
HEALTH LINE CLINICAL LABS SIGNS $10 MILLION FRAUD SETTLEMENT WITH FEDS
DESPITE THE EVIDENCE that packing unnecessary tests into test panels is not acceptable to Medicare and Medicaid authorities, some laboratories continue the practice.
Health Line Clinical Laboratories, Inc. (HLCL) of Burbank, California is the latest lab company to pay a significant fine to settle allegations of